首页> 外文期刊>Journal of the National Cancer Institute >C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management.
【24h】

C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management.

机译:结肠癌的C期:癌胚抗原生物标志物在分期,预后和管理中的意义。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The American Joint Committee on Cancer (AJCC) has proposed the inclusion of pretreatment serum carcinoembryonic antigen (CEA) level (C-stage) into the conventional TNM staging system of colon cancer. We assessed the prognosis of various stages of colon cancer after such an inclusion. METHODS: Data for all patients (N = 17 910) diagnosed with colonic adenocarcinoma (AJCC stages I, IIA, IIB, IIC, IIIA, IIIB, IIIC, and IV, based on TNM staging system) between January 1, 2004, and December 31, 2004, with a median follow-up of 27 months (range 0-35 months), were collected from the Surveillance, Epidemiology, and End Results database. C-stage (C0-stage = normal CEA level; C1-stage = elevated CEA level) was assigned to all patients with available CEA information (n = 9083). Multivariable analyses using Cox proportional hazards models were used to identify independent factors associated with prognosis. Prognosis of overall stages (AJCC stages I-IV and C0 or C1) was analyzed using Kaplan-Meier survival curves. All statistical tests were two-sided. RESULTS: C1-stage was independently associated with a 60% increased risk of overall mortality (hazard ratio of death = 1.60, 95% confidence interval = 1.46 to 1.76, P < .001). Overall survival was decreased in patients with C1-stage cancer compared with C0-stage cancer of the respective overall stages (P < .05). Similarly, decreased overall survival was noted in patients with stage I C1 cancer compared with stage IIA C0 or stage IIIA C0 cancer (P < .001), in patients with stage IIA C1 cancer compared with stage IIIA C0 (P < .001), and in patients with stage IIB C1 or stage IIC C1 cancer compared with stage IIIB C0 cancer (P < .001). CONCLUSIONS: C-stage was an independent prognostic factor for colon cancer. The results support routine preoperative CEA testing and C-staging upon diagnosis of colon cancer and the inclusion of C-stage in the conventional TNM staging of colon cancer.
机译:背景:美国癌症联合委员会(AJCC)提出将结肠癌常规TNM分期系统纳入治疗前血清癌胚抗原(CEA)水平(C期)。我们评估了纳入后结肠癌各个阶段的预后。方法:2004年1月1日至12月间,所有被诊断为结肠腺癌(AJCC I,IIA,IIB,IIC,IIIA,IIIB,IIIC和IV级,基于TNM分期系统)的患者(N = 17910)的数据从监测,流行病学和最终结果数据库中收集了2004年3月31日进行的中位随访27个月(0-35个月)。将C阶段(C0阶段=正常CEA水平; C1阶段=升高的CEA水平)分配给所有具有可用CEA信息的患者(n = 9083)。使用Cox比例风险模型进行多变量分析来确定与预后相关的独立因素。使用Kaplan-Meier生存曲线分析总体阶段(AJCC阶段I-IV和C0或C1)的预后。所有统计检验都是双面的。结果:C1期与整体死亡风险增加60%独立相关(死亡风险比= 1.60,95%置信区间= 1.46至1.76,P <.001)。与各个总体阶段的C0期癌症相比,C1期癌症患者的总体生存率降低(P <.05)。同样,与IIA C0期或IIIA C0期癌症相比,I C1期癌症患者的总体生存率下降(P <.001),与IIIA C0期相比与IIA C0期癌症的患者相比,总体生存率降低(P <.001),与IIB C1期或IIC C1期癌症患者相比,IIIB C0期癌症患者(P <.001)。结论:C期是结肠癌的独立预后因素。结果支持常规的术前CEA检测和结肠癌诊断时的C分期,以及常规结肠癌TNM分期中的C分期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号